Boston Scientific Can Expand Its Share In The U.S. Coronary Stent Market With Synergy BP-DES

Being the first to get the FDA approval for a bioabsorbable polymer drug-eluting stent (BP-DES), Boston Scientific has a huge opportunity to gain share in the interventional cardiology market in the the U.S., the largest coronary stent market. Coronary stent sales contribute significantly to Boston Scientific's Interventional Cardiology segment, which constitutes close to 30% of the company's value according to our estimates.